AstraZeneca says its $200M cash bet on Ionis’ ATTR drug is paying off — with PhIII data setting up FDA filing – Endpoints News
Mark Cuban made a big splash in the world of generic drugs when he launched a new company earlier this year, pledging to only charge a 15% mark-up for its generic drugs, and offering alternatives to a market often prone to shortages, and expensive options (think Martin Shkreli) often due to a lack of competition.
Widespread cost savings from using Cuban’s new company could be steep. A new study in the Annals of Internal Medicine took a look at almost 90 generic drugs that the Medicare Part D program pays for, finding that Medicare could’ve saved $3.6 billion in 2020 if it had purchased 77 of 89 drugs from Cuban’s firm.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,000+ biopharma pros reading Endpoints daily — and it’s free.